7 analysts have expressed a variety of opinions on Zevra Therapeutics (NASDAQ:ZVRA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Analysts have set 12-month price targets for Zevra Therapeutics, revealing an average target of $19.71, a high estimate of $25.00, and a low estimate of $15.00. This current average reflects an increase of 8.48%…